Related Experiment Videos
Multifactorial actions of beta-adrenergic blocking drugs in ischemic heart disease: current concepts
Insights
Beta blockers reduce myocardial oxygen demand by lowering heart rate and blood pressure, proving beneficial for treating myocardial ischemia. While their effects on coronary blood flow are debated, their overall profile supports their use in managing ischemic conditions.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Myocardial ischemia arises when oxygen demand outstrips supply, often due to coronary artery disease or vasospasm.
- Key factors influencing myocardial oxygen consumption include systemic wall tension, heart rate, and contractility.
- Beta-adrenergic stimulation increases oxygen demand, potentially worsening ischemia.
Purpose of the Study:
- To review the role of beta-adrenergic blocking drugs in managing myocardial ischemia.
- To explore the mechanisms by which beta blockers affect myocardial oxygen consumption and coronary blood flow.
- To evaluate the evidence supporting the use of beta blockers in preventing and treating myocardial ischemia.
Main Methods:
- Review of existing literature on beta blockers and myocardial ischemia.
- Analysis of hemodynamic effects of beta blockers on myocardial oxygen requirements.
- Examination of studies investigating beta blocker impact on coronary blood flow and related factors.
Main Results:
- Beta blockers decrease myocardial oxygen demand by reducing heart rate, blood pressure, and contractility.
- The impact of beta blockers on coronary blood flow is complex, with potential for both reduction and augmentation.
- Controversial findings exist regarding beta blockers' effects on myocardial metabolism, microvasculature, and collateral flow.
Conclusions:
- Beta blockers effectively reduce myocardial oxygen requirements, aiding in ischemia management.
- Despite some uncertainties regarding coronary blood flow, beta blockers possess a favorable pharmacologic profile for myocardial ischemia.
- Beta blockers are considered valuable in the prevention and treatment of myocardial ischemia.
Abstract:
It is generally agreed that the conditions leading to myocardial ischemia occur when the oxygen demands of the myocardium exceed the oxygen supply. The major limitations of oxygen supply to the myocardium are atherogenic disease and vasospasm of the coronary arteries. The major hemodynamic determinants of myocardial oxygen consumption are systemic wall tension, heart rate and the inotropic state of the myocardium. Stimulation of beta-adrenergic receptors in the heart by endogenous catecholamines increases myocardial oxygen consumption, which can aggravate the ischemic process. Beta-adrenergic blocking drugs decrease myocardial oxygen requirements by reducing systemic arterial pressure, heart rate and myocardial contractility at rest and during exercise, making them useful for treating ischemia. The effects of these drugs on coronary blood flow are less well defined. Beta blockers may decrease coronary blood flow by allowing the unopposed influence of coronary vasoconstrictor impulses to prevail. However, the drugs may also augment overall coronary blood flow by slowing the heart rate and increasing diastolic perfusion time. Controversial studies have shown favorable effects of beta blockers on myocardial metabolism and energetics, the coronary microvasculature, collateral blood flow, the distribution of myocardial blood flow, oxygen-hemoglobin affinity and platelet function. Although their exact antiischemic mechanisms are not known, beta blockers have an overall pharmacologic profile that favors their use in the prevention and treatment of myocardial ischemia.